Prelude Therapeutics Incorporated
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Equivalents | $35.3M | $12.5M | $25.3M | $30.6M | $31.8M | $218.3M | $18.9M |
| Accounts Receivable | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — |
| Total Current Assets | $105.7M | $135.9M | $235.6M | $204.4M | $295.1M | $220.8M | $20.2M |
| Property, Plant & Equipment | $5.1M | $6.8M | $7.3M | $4.9M | $3.9M | $2.5M | $1.6M |
| Goodwill | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — |
| Total Assets | $141.3M | $175.5M | $277.7M | $220.5M | $305.1M | $223.6M | $21.9M |
| Liabilities | |||||||
| Accounts Payable | $4.0M | $7.7M | $4.6M | $6.8M | $7.8M | $3.9M | $2.0M |
| Total Current Liabilities | $53.0M | $25.6M | $21.8M | $21.7M | $19.2M | $11.4M | $4.8M |
| Long-Term Debt | — | — | — | — | — | — | — |
| Total Liabilities | $72.7M | $44.1M | $40.6M | $25.1M | $19.2M | $11.4M | $4.8M |
| Stockholders' Equity | |||||||
| Retained Earnings | $-683.1M | $-583.6M | $-456.4M | $-334.6M | $-219.1M | $-107.4M | $-50.5M |
| Total Stockholders' Equity | $68.6M | $131.5M | $237.1M | $195.4M | $285.9M | $212.2M | $-49.4M |